# Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting
Ticker: CADL
Company: Candel Therapeutics
Source: Candel Therapeutics
Published: 2026-05-15 20:05 EST
Original Source URL: https://ir.candeltx.com
## Summary

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to

## Article Body
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to
## Recent Company News
- 2026-06-02 12:05 EST — [Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer) — Source: Candel Therapeutics
- 2026-05-15 20:05 EST — [Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting](https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting) — Source: Candel Therapeutics
- 2026-05-14 12:05 EST — [Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Candel Therapeutics
- 2026-05-13 12:05 EST — [Candel Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-at-upcoming-investor-conferences) — Source: Candel Therapeutics
- 2026-05-04 12:05 EST — [Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting](https://biopharmsignal.com/news/CADL/candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting) — Source: Candel Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)